Skip links

Keynotes from panel discussion on Cell and Gene Therapy (CGT) in Thailand  

Factorytalk organized a compelling roundtable discussion centered on Cell and Gene Therapy (CGT) in Thailand on 17 January 2024. This event invited industry leaders to bring together a cross-section of the Thai CGT community in its early stage, and to gather inputs on what is required for Thailand to be successful in the medium and long term as a center to supply Advanced Therapeutic Medicinal Products (ATMP’s). We are pleased to present a summary of the key findings and interesting takeaways from the panel discussion on Enablers & Opportunities for Thailand in the CGT landscape, relevant to CGT stakeholders including academia, regulators, healthcare providers, suppliers, and Thai pharma professionals. 

Panel Discussion Highlights: 

The panel discussion featured panelists: 

  • Dr. Shin Kawamata, CEO – Cyto-Facto, Inc. (Japan) 
  • Kittipong Uaesoontrachoon, Chief Scientific Officer – Genepeutic Bio Co., Ltd. 
  • Pharon Pawa, Chief Production Officer – Austrianova (Thailand) Co., Ltd. 

1. How Thailand can compete in Cell and Gene – Government policy and business infrastructure, notes on the panel discussion. 

Discussion Points: 

  • Weaknesses for Thailand to address in the area of CGT 
  • Key CGT Enablers for Thailand 
  • Opportunities for Better Collaboration 


2. Emerging investment areas for CGT  

Discussion points on  

  • Challenges in investment 
  • Investment areas 

To delve deeper into the insights shared during the discussion, fill out the form below to download the document and explore the comprehensive summary of the panel discussion. 

To learn more about CGT biomanufacturing, product characterizations, and regulatory-quality frameworks, register ISCT-CMaT CGT biomanufacturing training course at 

Leave a comment